Impel collaborates with researchers and thought leaders in CNS disease research, drug development and clinical research. Our research partners include some of the world’s largest pharmaceutical and biotechnology companies and premier academic research institutions, as well as specialty pharmaceutical companies and cutting edge start-ups.
Our business model is to license the POD technology to development partners, enabling their proprietary drug molecules to reach the brain faster, in greater amounts and with improved patient experience than alternate delivery methods such as intravenous or intrathecal dosing.
To explore how our innovative technology can be tailored to meet your needs, contact us.
